Floatz logo

Capecitabine

C04.588.274.476.411.307

Brigham and Women's HospitalSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the C04.588.274.476.411.307 cohort.

Asset / SponsorPhaseRating
Metformin
The First Affiliated Hospital of Xiamen University
Phase 4BBB
Sitagliptin
Dawn Smiley MD
Phase 4BB
Exenatide
Saint Luke's Health System
Phase 4BB
Olanzapine
Washington University School of Medicine
Phase 4BB
Saffron
Birjand University of Medical Sciences
Phase 4BB

View all 34 →

Same molecule, other indications

Capecitabine is also rated in:

Locally Advanced Rectal CancerDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →
rectal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →